<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089231</url>
  </required_header>
  <id_info>
    <org_study_id>GWLUH-001</org_study_id>
    <secondary_id>GWLUH2010</secondary_id>
    <nct_id>NCT01089231</nct_id>
  </id_info>
  <brief_title>Effects of Omega-3 Fatty Acids on the Human Gene Expression</brief_title>
  <official_title>Effects of Omega-3 Fatty Acids From Fish Oil on the Gene Expression in Healthy Humans and Humans With Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gottfried Wilhelm Leibniz Universität Hannover</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gottfried Wilhelm Leibniz Universität Hannover</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effects of short- and long-term intervention with
      EPA and DHA-rich fish oil on gene expression profiles in healthy and hyperlipidemic males.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular and coronary heart diseases continue to be the leading causes of morbidity and
      mortality among adults in Europe and North America. Since the number of elderly people and
      therefore the number of chronic-inflammatory diseases rise, preventive therapies become more
      important. Within preventive strategies, nutrition plays a central role.

      Cross-sectional studies suggested that omega-3 fatty acids, especially the very long-chain
      fatty acids Eicosapentaenoic acid (EPA, C20:5ω3) and Docosahexaenoic acid (DHA, C22:6ω3), are
      protective against cardiovascular and coronary heart diseases. Their cardio protective
      potential is based on their positive effects on blood lipids, vascular tonus and blood
      clotting. A number of controlled clinical trials have shown that EPA and DHA supplementation
      lower fasting and postprandial plasma concentrations of triglyceride-rich lipoproteins and
      their remnants. Biochemical research revealed numerous metabolic effects of EPA and DHA,
      ranging from their effects on membrane fluidity to the modification of the eicosanoid
      profile.

      However, only a few human clinical trials examined the regulative effects of DHA and EPA
      supplementation on gene expression. Furthermore, to our knowledge no published research data
      is available dealing with the effect of these fatty acids on gene expression in subjects with
      hypertriglyceridemia in comparison to healthy subjects. Such findings are of great concern
      due to hints that especially people with hypertriglyceridemia benefit from the triglyceride
      lowering effect of EPA and DHA supplementation. Presently it is not well-established if the
      gene regulative potential of EPA and DHA in these persons differs from healthy persons. These
      findings could help to understand the differences in the metabolic effects of EPA and DHA in
      healthy vs. hypertriglyceridemic persons, which have a greater risk for cardiovascular and
      coronary diseases. Finally, these data could contribute to a knowledge basis for targeted
      strategies in preventive therapies with the very long-chain omega-3 fatty acids EPA and DHA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gene Expression Changes</measure>
    <time_frame>Gene expression changes (number of regulated genes)</time_frame>
    <description>Gene expression changes were measured by using whole genome microarrays. The expression values of all genes were compared between baseline and 4 hours, 7 days and twelve weeks after supplementation with FO or CO and differentially expressed genes were detected by standard two-state pooled-variance t-test (p&lt;0,05). The number of differentially expressed genes (regulated genes)compared to the baseline values were determined for every study group in total as well as for every time point (4 hours, 7 days, 12 weeks)in total and specifically.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatty Acid Composition of Erythrocyte Membranes (Omega-3 Index)</measure>
    <time_frame>baseline and after 12 weeks</time_frame>
    <description>Fasting venous blood samples were collected and RBC membrane FA composition including the omega-3 index, given as EPA + DHA, was analyzed at baseline and after 12 weeks according to the omega-3 index methodology (Harris &amp; von Schacky, 2004). Results are presented as a percentage of the total identified FAs after response factor correction. The coefficient of variation for EPA + DHA was 5%. Quality was assured according to DIN ISO 15189.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Lipids</measure>
    <time_frame>baseline and after 12 weeks</time_frame>
    <description>Fasting venous blood samples were collected and blood lipid levels were determined by an external contract laboratory (LADR, Hannover; Germany) at baseline (t0), after one week (t1) and after 12 weeks (t12) of supplementation.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hyperlipidemia</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo - healthy subjects</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary Supplement: corn oil capsules (6 per day) about 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - hyperlipedemic subjects</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary Supplement: corn oil capsules (6 per day) about 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish oil - hyperlipidemic subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish oil - healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil</intervention_name>
    <description>Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months</description>
    <arm_group_label>Fish oil - hyperlipidemic subjects</arm_group_label>
    <arm_group_label>Fish oil - healthy subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo (corn oil)</intervention_name>
    <description>corn oil (6 capsules per day)</description>
    <arm_group_label>Placebo - healthy subjects</arm_group_label>
    <arm_group_label>Placebo - hyperlipedemic subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males, 20-50 years

          -  non-smokers

          -  ethnicity: Caucasians

          -  no medical treatment

          -  healthy subjects:

               -  no documented disease

               -  normal blood lipids (triglyceride &lt; 150 mg/dl; total cholesterol &lt; 200 mg/dl)

          -  humans with increased blood lipids (hyperlipidemia)

               -  documented hypertriglyceridemia or

               -  triglyceride ≥ 150 mg/dl (≥ 1,7 mmol/l) and

               -  total cholesterol &gt; 200 mg/dl (5,2 mmol/l)

          -  written confirmation of the subjects after detailed oral and written explanation about
             the study contents, - requirements and risks

          -  ability and willingness of the participants to attend the investigator's orders
             (compliance of the study conditions, consumption of the study medicaments according to
             the dosage commendation)

        Exclusion Criteria:

          -  Body-Mass-Index (BMI) ≥ 35

          -  smokers

          -  medical treatment (especially corticosteroids, anti-inflammatory drugs, blood lipids
             lowering drugs (e.g. statins, fibrates, bile acid exchanger resin, phytosterols)

          -  taking any supplements with omega-3 fatty acids, phytosterols, polyglucosamines
             (Chitosan) or other lipid binding ingredients

          -  daily consumption of omega-3 fatty acids rich fish (salmon, mackerel, herring)

          -  heavy chronic diseases (tumors, diabetes typ 1, etc.), documented heart disease,
             documented blood clotting disorders, renal failure, liver diseases

          -  documented blood clotting disorders and consumption of coagulation-inhibiting drugs
             (for example Marcumar, ASS)

          -  allergy or intolerance to fish/fish oil or any of the study ingredients of the test
             products

          -  chronic gastro-intestinal diseases (Colitis ulcerosa, Morbus Crohn, pancreatic
             insufficiency)

          -  donation of blood in the last 6 weeks

          -  routine consumption of laxative

          -  common exclusion criteria like

               -  alcohol-, drug- and/or medicament dependence

               -  subjects who are not in agreement with the study conditions

               -  refusal or rather reset of the consent from the subject

               -  active participation in other investigational drug or device trial within the
                  last 30 days
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>51 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Hahn, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Gottfried Wilhelm Leibniz University of Hanover</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gottfried Wilhelm Leibniz University of Hanover</name>
      <address>
        <city>Hanover</city>
        <state>Lower Saxony</state>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.nutrition.uni-hannover.de</url>
    <description>web page of the institute</description>
  </link>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <results_first_submitted>October 27, 2011</results_first_submitted>
  <results_first_submitted_qc>October 27, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2011</results_first_posted>
  <last_update_submitted>December 12, 2011</last_update_submitted>
  <last_update_submitted_qc>December 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gottfried Wilhelm Leibniz Universität Hannover</investigator_affiliation>
    <investigator_full_name>M. Sc. Simone Schmidt</investigator_full_name>
    <investigator_title>Master of Science</investigator_title>
  </responsible_party>
  <keyword>Hyperlipidemia</keyword>
  <keyword>coronary heart disease</keyword>
  <keyword>gene expression</keyword>
  <keyword>fish oil</keyword>
  <keyword>DHA, EPA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment of subjects was performed by several advertisements and study placards in hanover from january until february 2010. By a telephonic preselection 106 subjects were selected according to inclusion criteria.</recruitment_details>
      <pre_assignment_details>Serum lipid levels of the preselected subjects were determined and 20 normolipidemic and 20 dyslipidemic men were enrolled in the study population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo - Healthy Subjects</title>
          <description>Dietary Supplement: corn oil capsules (6 per day) about 3 months n=6</description>
        </group>
        <group group_id="P2">
          <title>Placebo - Hyperlipedemic Subjects</title>
          <description>Dietary Supplement: corn oil capsules (6 per day) about 3 months n=8</description>
        </group>
        <group group_id="P3">
          <title>Fish Oil - Hyperlipidemic Subjects</title>
          <description>Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months n=8</description>
        </group>
        <group group_id="P4">
          <title>Fish Oil - Healthy Subjects</title>
          <description>Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months. n=9</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6">4 subjects excluded (2 alcohol use / TG level changes; 1 use of not allowed drugs; 1 low RNA yield)</participants>
                <participants group_id="P2" count="8">2 subjects excluded (1 highly elevated TG and TC data; 1 elevated inflammation (CRP level))</participants>
                <participants group_id="P3" count="8">2 subject excluded (1 use of not allowed drugs; 1 low RNA yield)</participants>
                <participants group_id="P4" count="9">1 subject excluded (low RNA yield)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo - Healthy Subjects</title>
          <description>Dietary Supplement: corn oil capsules (6 per day) about 3 months n=6</description>
        </group>
        <group group_id="B2">
          <title>Placebo - Hyperlipedemic Subjects</title>
          <description>Dietary Supplement: corn oil capsules (6 per day) about 3 months n=8</description>
        </group>
        <group group_id="B3">
          <title>Fish Oil - Hyperlipidemic Subjects</title>
          <description>Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months n=8</description>
        </group>
        <group group_id="B4">
          <title>Fish Oil - Healthy Subjects</title>
          <description>Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months. n=9</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.4" spread="8.30"/>
                    <measurement group_id="B2" value="41.8" spread="8.94"/>
                    <measurement group_id="B3" value="40.2" spread="8.64"/>
                    <measurement group_id="B4" value="37.5" spread="8.11"/>
                    <measurement group_id="B5" value="38.82" spread="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Gene Expression Changes</title>
        <description>Gene expression changes were measured by using whole genome microarrays. The expression values of all genes were compared between baseline and 4 hours, 7 days and twelve weeks after supplementation with FO or CO and differentially expressed genes were detected by standard two-state pooled-variance t-test (p&lt;0,05). The number of differentially expressed genes (regulated genes)compared to the baseline values were determined for every study group in total as well as for every time point (4 hours, 7 days, 12 weeks)in total and specifically.</description>
        <time_frame>Gene expression changes (number of regulated genes)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Healthy Subjects</title>
            <description>Dietary Supplement: corn oil capsules (6 per day) about 3 months n=6</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Hyperlipedemic Subjects</title>
            <description>Dietary Supplement: corn oil capsules (6 per day) about 3 months n=8</description>
          </group>
          <group group_id="O3">
            <title>Fish Oil - Hyperlipidemic Subjects</title>
            <description>Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months n=8</description>
          </group>
          <group group_id="O4">
            <title>Fish Oil - Healthy Subjects</title>
            <description>Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months. n=9</description>
          </group>
        </group_list>
        <measure>
          <title>Gene Expression Changes</title>
          <description>Gene expression changes were measured by using whole genome microarrays. The expression values of all genes were compared between baseline and 4 hours, 7 days and twelve weeks after supplementation with FO or CO and differentially expressed genes were detected by standard two-state pooled-variance t-test (p&lt;0,05). The number of differentially expressed genes (regulated genes)compared to the baseline values were determined for every study group in total as well as for every time point (4 hours, 7 days, 12 weeks)in total and specifically.</description>
          <units>number of regulated genes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>total (4 hours+7 days+12weeks,without doubles)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="841"/>
                    <measurement group_id="O2" value="1041"/>
                    <measurement group_id="O3" value="1639"/>
                    <measurement group_id="O4" value="628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours (total)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320"/>
                    <measurement group_id="O2" value="436"/>
                    <measurement group_id="O3" value="508"/>
                    <measurement group_id="O4" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 days (total)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418"/>
                    <measurement group_id="O2" value="629"/>
                    <measurement group_id="O3" value="1105"/>
                    <measurement group_id="O4" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks (total)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500"/>
                    <measurement group_id="O2" value="493"/>
                    <measurement group_id="O3" value="1027"/>
                    <measurement group_id="O4" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours (specific)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="246"/>
                    <measurement group_id="O4" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 days (specific)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="242"/>
                    <measurement group_id="O3" value="326"/>
                    <measurement group_id="O4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks (specific)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312"/>
                    <measurement group_id="O2" value="287"/>
                    <measurement group_id="O3" value="203"/>
                    <measurement group_id="O4" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatty Acid Composition of Erythrocyte Membranes (Omega-3 Index)</title>
        <description>Fasting venous blood samples were collected and RBC membrane FA composition including the omega-3 index, given as EPA + DHA, was analyzed at baseline and after 12 weeks according to the omega-3 index methodology (Harris &amp; von Schacky, 2004). Results are presented as a percentage of the total identified FAs after response factor correction. The coefficient of variation for EPA + DHA was 5%. Quality was assured according to DIN ISO 15189.</description>
        <time_frame>baseline and after 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Healthy Subjects</title>
            <description>Dietary Supplement: corn oil capsules (6 per day) about 3 months n=6</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Hyperlipedemic Subjects</title>
            <description>Dietary Supplement: corn oil capsules (6 per day) about 3 months n=8</description>
          </group>
          <group group_id="O3">
            <title>Fish Oil - Hyperlipidemic Subjects</title>
            <description>Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months n=8</description>
          </group>
          <group group_id="O4">
            <title>Fish Oil - Healthy Subjects</title>
            <description>Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months. n=9</description>
          </group>
        </group_list>
        <measure>
          <title>Fatty Acid Composition of Erythrocyte Membranes (Omega-3 Index)</title>
          <description>Fasting venous blood samples were collected and RBC membrane FA composition including the omega-3 index, given as EPA + DHA, was analyzed at baseline and after 12 weeks according to the omega-3 index methodology (Harris &amp; von Schacky, 2004). Results are presented as a percentage of the total identified FAs after response factor correction. The coefficient of variation for EPA + DHA was 5%. Quality was assured according to DIN ISO 15189.</description>
          <units>percentage of total fatty acids</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>omega-3 index baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08" spread="1.41"/>
                    <measurement group_id="O2" value="5.27" spread="1.69"/>
                    <measurement group_id="O3" value="4.90" spread="1.80"/>
                    <measurement group_id="O4" value="5.24" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>omega-3 index after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" spread="1.16"/>
                    <measurement group_id="O2" value="5.50" spread="1.57"/>
                    <measurement group_id="O3" value="9.84" spread="1.26"/>
                    <measurement group_id="O4" value="10.7" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Lipids</title>
        <description>Fasting venous blood samples were collected and blood lipid levels were determined by an external contract laboratory (LADR, Hannover; Germany) at baseline (t0), after one week (t1) and after 12 weeks (t12) of supplementation.</description>
        <time_frame>baseline and after 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Healthy Subjects</title>
            <description>Dietary Supplement: corn oil capsules (6 per day) about 3 months n=6</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Hyperlipedemic Subjects</title>
            <description>Dietary Supplement: corn oil capsules (6 per day) about 3 months n=8</description>
          </group>
          <group group_id="O3">
            <title>Fish Oil - Hyperlipidemic Subjects</title>
            <description>Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months n=8</description>
          </group>
          <group group_id="O4">
            <title>Fish Oil - Healthy Subjects</title>
            <description>Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months. n=9</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Lipids</title>
          <description>Fasting venous blood samples were collected and blood lipid levels were determined by an external contract laboratory (LADR, Hannover; Germany) at baseline (t0), after one week (t1) and after 12 weeks (t12) of supplementation.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>total cholesterol (TC) baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194.0" spread="22.2"/>
                    <measurement group_id="O2" value="261.0" spread="48.1"/>
                    <measurement group_id="O3" value="262.2" spread="61.9"/>
                    <measurement group_id="O4" value="184.1" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total cholesterol (TC) after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.9" spread="21.5"/>
                    <measurement group_id="O2" value="257.5" spread="60.3"/>
                    <measurement group_id="O3" value="264.4" spread="49.2"/>
                    <measurement group_id="O4" value="198.6" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>low-density lipoprotein (LDL) baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.1" spread="25.1"/>
                    <measurement group_id="O2" value="178.1" spread="45.4"/>
                    <measurement group_id="O3" value="146.1" spread="5.31"/>
                    <measurement group_id="O4" value="108.7" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>low-density lipoprotein (LDL) after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.6" spread="28.2"/>
                    <measurement group_id="O2" value="172.6" spread="54.4"/>
                    <measurement group_id="O3" value="167.4" spread="23.6"/>
                    <measurement group_id="O4" value="117.2" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>high-density lipoprotein (HDL) baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7" spread="12.7"/>
                    <measurement group_id="O2" value="47.9" spread="10.0"/>
                    <measurement group_id="O3" value="45.2" spread="6.5"/>
                    <measurement group_id="O4" value="59.0" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>high-density lipoprotein (HDL) after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" spread="11.6"/>
                    <measurement group_id="O2" value="47.4" spread="8.21"/>
                    <measurement group_id="O3" value="50.8" spread="9.43"/>
                    <measurement group_id="O4" value="65.2" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>triacylglycerol (TG) baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.6" spread="53.8"/>
                    <measurement group_id="O2" value="175.0" spread="56.2"/>
                    <measurement group_id="O3" value="322.4" spread="259.0"/>
                    <measurement group_id="O4" value="82.4" spread="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>triacylglycerol (TG) after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.4" spread="14.8"/>
                    <measurement group_id="O2" value="186.9" spread="49.6"/>
                    <measurement group_id="O3" value="230.8" spread="147.0"/>
                    <measurement group_id="O4" value="66.2" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo - Healthy Subjects</title>
          <description>Dietary Supplement: corn oil capsules (6 per day) about 3 months n=6</description>
        </group>
        <group group_id="E2">
          <title>Placebo - Hyperlipedemic Subjects</title>
          <description>Dietary Supplement: corn oil capsules (6 per day) about 3 months n=8</description>
        </group>
        <group group_id="E3">
          <title>Fish Oil - Hyperlipidemic Subjects</title>
          <description>Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months n=8</description>
        </group>
        <group group_id="E4">
          <title>Fish Oil - Healthy Subjects</title>
          <description>Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months. n=9</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.05</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A higher number of participants would be better to compensate drop outs
two pre-screening procedures of lipid levels are generally desirable
CO is not an optimal placebo control</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>M. Sc. Simone Schmidt</name_or_title>
      <organization>Leibniz Universität Hannover</organization>
      <phone>+49 (511) 762 5931</phone>
      <email>Schmidt@nutrition.uni-hannover.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

